ArticleCancer cell2018
Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer.
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Proliferative Tumor States and Immunogenic Ecosystems Predict Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer.Biomedicines · 2026Article
- Regulation of glycosylation in radiotherapy: exploring the multiple effects of DNA damage, immune response, stromal microenvironment and metabolism.Frontiers in oncology · 2026Review
- DPAGT1-Perspective as an Anticancer Drug Target.Molecules (Basel, Switzerland) · 2025Review
- Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers.Cells · 2024Review
- Saturation Transfer Difference NMR and Molecular Docking Interaction Study of Aralkyl-Thiodigalactosides as Potential Inhibitors of the Human-Galectin-3 Protein.International journal of molecular sciences · 2024Article
- Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer.Nature communications · 2023Article
- Glycosylation Alterations in Cancer Cells, Prognostic Value of Glycan Biomarkers and Their Potential as Novel Therapeutic Targets in Breast Cancer.Biomedicines · 2022Review
- Investigation of the Molecular Details of the Interactions of Selenoglycosides and Human Galectin-3.International journal of molecular sciences · 2022Article
- ATP2C2 Has Potential to Define Tumor Microenvironment in Breast Cancer.Frontiers in immunology · 2021Article
- Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence.Frontiers in pharmacology · 2021Article
- ZW10 Binding Factor (ZWINT), a Direct Target of Mir-204, Predicts Poor Survival and Promotes Proliferation in Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Glycosylation and its implications in breast cancer.Expert review of proteomics · 2019Review
- Glycans as Biomarkers in Prostate Cancer.International journal of molecular sciences · 2019Review
- Long Non-coding RNA LINC01787 Drives Breast Cancer Progression via Disrupting miR-125b Generation.Frontiers in oncology · 2019Article
- Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.Frontiers in immunology · 2019Review
- Classification of triple-negative breast cancers based on Immunogenomic profiling.Journal of experimental & clinical cancer research : CR · 2018Article
- Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.Trends in biochemical sciences · 2018Review
- Improving Immunotherapy Through Glycodesign.Frontiers in immunology · 2018Review
- Each pregnancy linearly changes immune gene expression in the blood of healthy women compared with breast cancer patients.Clinical epidemiology · 2018Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.